Profiling Epidermal Growth Factor Receptor DNA Mutations In Circulating Rare Cells Using A Cell Isolation System And Droplet Digital PCR.
A specialized blood test captures cancer DNA directly from rare circulating tumor cells when standard plasma tests yield insufficient material.
This methodological study (JoVE video protocol format) demonstrates a workflow combining a specialized cell isolation system with droplet digital PCR to detect EGFR mutations in circulating rare cells from blood of lung cancer patients, offering a distinct liquid biopsy approach that captures mutation information from rare cells rather than cell-free DNA. The method provides a technically validated alternative for cases where plasma ctDNA yield is insufficient, though clinical validation in larger cohorts is needed.
What the study was
- Study design
- Proof-of-concept method validation study (video protocol article)
- Population
- Lung cancer patients; circulating rare cells and ctDNA from blood samples
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Journal of visualized experiments : JoVE
Why it surfaced
Technical liquid biopsy method addressing EGFR mutation detection in lung cancer via circulating rare cells; relevant for precision oncology monitoring but requires larger clinical validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.